LICEPLER PRESS RELEASE
IASIS PHARMA has launched a new pharmaceutical product under the brand name Licepler (Eplerenone). Licepler is specifically indicated for the reduction of risk of cardiovascular death in people with heart failure and left ventricular dysfunction ≤40% after a recent acute myocardial infarction, in combination with standard therapies and as treatment against hypertension. Licepler (25mg/f.c. tab [...]